Allan Kengo

Allan is a pharmacist currently pursuing a Ph.D. in pharmacometrics at the University of Cape Town.

He holds a Bachelor of Pharmacy degree and a M.Sc. degree in Pharmacology and Therapeutics from Makerere University, Uganda.

His previous work investigated pharmacogenetic predictors of variability in rifampicin pharmacokinetics in Ugandan HIV negative TB patients.

He is currently working on the SAEFRIF project, which is investigating the safety, tolerability, and effect of high dose rifampicin on the pharmacokinetics of Efavirenz/Dolutegravir in TB-HIV co-infected patients.

Allan joined the Pharmacometrics group at UCT, as a Ph.D. student in February 2021. He holds a Bachelor of Pharmacy degree and a M.Sc. degree in Pharmacology and Therapeutics from Makerere University, Uganda. His previous work investigated pharmacogenetic predictors of variability in rifampicin pharmacokinetics in Ugandan HIV negative TB patients.

Current research Projects

• SAEFRIF project, which is investigating the safety, tolerability, and effect of high dose rifampicin on the pharmacokinetics of Efavirenz/Dolutegravir in TB-HIV co-infected patients.

Research interests

• Nonlinear mixed effects modeling of Pharmacokinetics and Pharmacodynamics of drugs used in the treatment of Tuberculosis and HIV.